Global Health
- Market cap
- ₹ 31,449 Cr.
- P/E
- 60.2x
- P/B
- 8.13x
- 52-week range
- 956 – 1,544
- ROE
- 15%
- ROCE
- 17%
- Dividend yield
- 0%
- Debt / equity
- 0.3
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Global Health Limited (Medanta) is an India-based multi-specialty tertiary care provider in the North and East regions of India. Medanta delivers advanced, end-to-end healthcare in Delhi, Gurugram, Indore, Ranchi, Patna, and Lucknow through its network of approximately five hospitals. Medanta provides healthcare services in over 30 medical specialties and engages over 1,800 doctors. Its specialty treatments are in cardiac care, cancer care, neurosciences, orthopedics, renal care, liver transplants, oncology, bone marrow transplant, obstetrics and gynecology, chest surgery, lung transplant, pediatric care, ENT, head and neck surgery, and others. Its facilities and services include medicine delivery, lab tests & diagnostics, homecare services, health checkups, elder care, air ambulance, among others. Its subsidiaries include Global Health Patliputra Private Limited, Medanta Holdings Private Limited, and GHL Pharma & Diagnostic Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Global Health against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)60.2 against a typical 48.9: pricier than most peers (1st = cheapest).25th of 40
- Sales growth+26.5% against a typical +21.1% from a year earlier.13th of 34
- Profit growth−1.3% against a typical +13% from a year earlier.23rd of 31
- Share price, 3 months−10.1% against a typical −10.9%.17th of 34
- Size₹ 31,448.8 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).7th of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil AA | Stable | 16 Dec 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 16 Dec 2025 | ▲ Upgrade1 notch | Crisil AA- → Crisil AA | — | CRISIL | ₹ 1,500 Cr. | |
| 16 Oct 2025 | Rating action | Crisil AA- | — | CRISIL | ₹ 1,500 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 30 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 14 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the quarter and year ended March 31, 2026 and recommendation of final dividend, if any subject to shareholders approval. |
| 4 Feb 2026 | Financial Results | To consider and approve the financial results for the Third Quarter and Nine Months ended December 31, 2025. |
| 7 Nov 2025 | Financial Results | To consider and approve the un-audited financial results for the period ended September 30, 2025 |
| 7 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 15 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the quarter and year ended March 31, 2025 and recommend the final dividend, if any subject to shareholders approval. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Expenses | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 |
| Operating Profit | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 |
| OPM % | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% |
| Other Income | 21 | 18 | 27 | 22 | 18 | 16 | −27 | 20 | 36 | −15 | 37 | 22 |
| Interest | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 |
| Depreciation | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 |
| Profit before tax | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 |
| Tax % | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% |
| Net Profit | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| EPS in Rs | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.9 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 12%
- 5 Years
- 25%
- 3 Years
- 18%
- TTM
- 21%
- 10 Years
- 13%
- 5 Years
- 81%
- 3 Years
- 20%
- TTM
- 0%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 27%
- TTM
- —
- 10 Years
- —
- 5 Years
- 16%
- 3 Years
- 16%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Global Health | ₹ 1,288.20 | ₹ 31,449 Cr. | 60.2x | 8.1x | 15% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Naresh Trehan
- Executive Chairman, Managing Director
- Pankaj Prakash Sahni
- Group Chief Executive Officer, Whole Time Director
- Yogesh Kumar Gupta
- Chief Financial Officer
- Rahul Ranjan
- Compliance Officer, Company Secretary
- Malik Mohd Ashhab
- Head - Diagnostic Services
- Mahi Tandon
- Hospital Director - Medanta Noida Unit
Prices are delayed and for information only. Nothing on this page is investment advice.